BioCentury
ARTICLE | Clinical News

HQK-1004: Phase II started

August 16, 2010 7:00 AM UTC

HemaQuest began an open-label, international Phase II trial to evaluate HQK-1004 plus IV ganciclovir for 5 days followed by oral valganciclovir for 16 days of each 3-week cycle for up to 6 cycles in u...